Previous studies suggested that increased HSD11B1 expression was interconnected with poor survival of ccRCC patients, supporting that HSD11B1 have the potential to be a prognostic biomarker in patients with ccRCC receiving immunotherapy. Here, HSD11B1 is linked to nonpapillary renal cell carcinoma.